Newswise — COLUMBUS, Ohio – There’s good news when it comes to our heart’s sinoatrial node (SAN), the body’s natural pacemaker. Scientists at The Ohio State University Wexner Medical Center have shown the human SAN is hardwired with a backup system — three diverse regions of pacemakers acting as batteries and up […]
Author: Ken Dropiewski
Bolton Medical Announces the First Implant in the TREO® Global Registry
Sunrise, Fla, July 21, 2017 – Today announced the first implant of the TREO Abdominal Stent Graft System in the TREO Registry: a Post-Market Surveillance Clinical Investigation that aims to assess long term real-world data of the TREO Technology in a Global, Prospective, Multicenter and Observational Study. The technology that will […]
Penumbra Schedules Second Quarter 2017 Earnings Release And Conference Call For August 8, 2017 At 4:30 PM Eastern Time
ALAMEDA, Calif., July 25, 2017 /PRNewswire/ — Penumbra, Inc.(NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2017 after market close on Tuesday, August 8, 2017 at 4:30 PM Eastern Time. A press release with second quarter 2017 financial results will be issued after market close […]
Corindus Vascular Robotics To Report Second Quarter 2017 Financial Results On August 8, 2017
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter of 2017 after the close of trading on Tuesday, August 8, 2017. The Company’s management team will host a corresponding conference […]
Medtronic (MDT) First To Receive Health Canada Licence For MR-Conditional Cardiac Resynchronization Therapy-Defibrillators
BRAMPTON, Ontario, July 26, 2017 (GLOBE NEWSWIRE) — Medtronic Canada, a subsidiary of Medtronic plc, today announced it has received a Health Canada licence and is launching its first and only magnetic resonance imaging (MRI) conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for heart failure. Heart failure causes or contributes to […]
SurModics (SRDX) Receives IDE Approval To Initiate Pivotal Trial Of The Surveil Drug-Coated Balloon
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal clinical trial of the SurVeil™ drug-coated balloon (DCB). The randomized […]
BioCardia Completes Roll-In Cohort In Pivotal Phase III CardiAMP Heart Failure Trial
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced completion of treatment for the 10-patient roll-in cohort for the pivotal Phase III CardiAMP Heart Failure Trial. A pre-specified review of the 30-day outcomes in this cohort by the Data […]
Penumbra initiates recall of 3D Revascularation Device
Penumbra Inc. Recalls 3D Revascularization Device Due to Wire Material That May Break or Separate During Use Penumbra Inc. is recalling the Penumbra 3D Revascularization device because there is a risk of the delivery wire breaking or separating during use. Fractured pieces of the delivery wire could be left inside […]
The Cath Lab of the Future is Here
JULY 26, 2017 BY Ken Dropiewski (ken@prime-core.com) In March, Miami Cardiac & Vascular Institute announced completion of its state-of-the-art cath lab, with the first next ten image-guided therapy system was being designed to reduce radiation exposure, decrease prep and procedure time and visually eliminate human error in the preparation and treatment […]
ABBOTT INITIATES CLINICAL TRIAL OF THREE-MONTH DUAL ANTIPLATELET THERAPY FOLLOWING IMPLANTATION WITH XIENCE CORONARY STENT
PRESS RELEASE ABBOTT PARK, Ill., July 25, 2017 — Abbott today announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a XIENCE everolimus-eluting coronary stent. The study, called XIENCE Short DAPT, […]



